## Supplemental Tables

## Protein Carbonylation in a Murine Model for Early Alcoholic Liver Disease

James J. Galligan<sup>1</sup>, Rebecca L. Smathers<sup>2</sup>, Kristofer S. Fritz<sup>2</sup>, L. Elaine Epperson<sup>3</sup>, Lawrence E. Hunter<sup>3</sup> and Dennis R. Petersen<sup>2</sup>\*

<sup>1</sup> Department of Pharmacology, School of Medicine, University of Colorado Denver, Aurora, CO. <sup>2</sup> Molecular Toxicology and Environmental Health Sciences Program, Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO. <sup>3</sup> Center for Computational Pharmacology, University of Colorado Denver, Aurora, CO 80045, USA

**Table S1.** Composite list of proteins identified in this study. The assigned protein accession number, protein name, molecular weight, protein fraction, treatment group, unique spectra, total spectra and sequence coverage are indicated.

**Table S2.** DAVID analysis demonstrates key metabolic pathways and processes implicated in the pathogenesis of ALD. Count pertains to the number of proteins contained in the enriched category; % reveals the percentage of proteins identified in our list that were enriched in the given term. Only terms with a fold-enrichment greater than 5.0 and a Benjamini corrected *P* value less than 0.01 were included.